Ningxia Zhongke Biotechnology Co., Ltd. Logo

Ningxia Zhongke Biotechnology Co., Ltd.

600165.SS

(0.0)
Stock Price

2,09 CNY

-31.66% ROA

-757.39% ROE

-1.81x PER

Market Cap.

1.362.919.160,00 CNY

-252.64% DER

0% Yield

-255.36% NPM

Ningxia Zhongke Biotechnology Co., Ltd. Stock Analysis

Ningxia Zhongke Biotechnology Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Ningxia Zhongke Biotechnology Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Negative ROE (-70.18%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (-12.05%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

3 PBV

The stock's high Price-to-Book Value (P/BV) ratio (6.12x) suggests it's overvalued, potentially making it an expensive investment.

4 DER

The company has a high debt to equity ratio (243%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-2) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Ningxia Zhongke Biotechnology Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Ningxia Zhongke Biotechnology Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Ningxia Zhongke Biotechnology Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Ningxia Zhongke Biotechnology Co., Ltd. Revenue
Year Revenue Growth
1995 159.160.019
1996 179.950.516 11.55%
1997 207.454.238 13.26%
1998 217.560.226 4.65%
1999 236.704.860 8.09%
2000 336.526.549 29.66%
2001 373.154.087 9.82%
2002 366.900.946 -1.7%
2003 467.133.942 21.46%
2004 644.426.235 27.51%
2005 710.776.831 9.33%
2006 847.751.525 16.16%
2007 1.030.817.691 17.76%
2008 1.474.291.659 30.08%
2009 1.525.671.551 3.37%
2010 1.618.113.451 5.71%
2011 1.676.990.129 3.51%
2012 1.841.805.596 8.95%
2013 1.763.903.207 -4.42%
2014 1.343.165.677 -31.32%
2015 1.076.651.547 -24.75%
2016 2.785.053.869 61.34%
2017 1.247.939.683 -123.17%
2018 552.087.908 -126.04%
2019 265.756.858 -107.74%
2020 119.114.953 -123.11%
2021 192.386.865 38.09%
2022 681.133.614 71.75%
2023 266.482.305 -155.6%
2023 285.688.730 6.72%
2024 230.238.520 -24.08%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Ningxia Zhongke Biotechnology Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 332.175 100%
2005 124.475 -166.86%
2006 1.907.310 93.47%
2007 0 0%
2008 0 0%
2009 0 0%
2010 1.634.484 100%
2011 2.397.569 31.83%
2012 1.597.018 -50.13%
2013 1.619.771 1.4%
2014 3.156.434 48.68%
2015 2.153.006 -46.61%
2016 13.440.529 83.98%
2017 1.542.282 -771.47%
2018 711.509 -116.76%
2019 1.635.132 56.49%
2020 964.883 -69.46%
2021 20.467.396 95.29%
2022 25.508.457 19.76%
2023 17.205.663 -48.26%
2023 13.873.396 -24.02%
2024 11.857.572 -17%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Ningxia Zhongke Biotechnology Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 6.873.545
1996 6.922.528 0.71%
1997 8.983.417 22.94%
1998 5.500.310 -63.33%
1999 13.860.877 60.32%
2000 13.946.536 0.61%
2001 15.985.543 12.76%
2002 11.957.243 -33.69%
2003 43.329.294 72.4%
2004 10.422.162 -315.74%
2005 21.255.136 50.97%
2006 25.102.136 15.33%
2007 34.494.837 27.23%
2008 44.383.501 22.28%
2009 52.414.871 15.32%
2010 12.859.474 -307.6%
2011 12.759.179 -0.79%
2012 11.124.444 -14.69%
2013 15.457.481 28.03%
2014 15.646.112 1.21%
2015 16.113.653 2.9%
2016 20.397.552 21%
2017 12.304.002 -65.78%
2018 13.499.124 8.85%
2019 9.227.582 -46.29%
2020 6.576.052 -40.32%
2021 6.114.066 -7.56%
2022 9.596.222 36.29%
2023 244.505.766 96.08%
2023 9.780.992 -2399.81%
2024 -9.937.766 198.42%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Ningxia Zhongke Biotechnology Co., Ltd. EBITDA
Year EBITDA Growth
1995 28.887.368
1996 31.881.600 9.39%
1997 37.779.557 15.61%
1998 43.098.265 12.34%
1999 50.457.497 14.59%
2000 98.465.781 48.76%
2001 96.756.216 -1.77%
2002 79.884.457 -21.12%
2003 29.479.492 -170.98%
2004 65.649.355 55.1%
2005 63.742.380 -2.99%
2006 30.230.365 -110.86%
2007 84.870.583 64.38%
2008 103.471.576 17.98%
2009 62.370.570 -65.9%
2010 49.452.852 -26.12%
2011 103.415.546 52.18%
2012 147.223.737 29.76%
2013 141.703.467 -3.9%
2014 84.679.671 -67.34%
2015 207.423.101 59.18%
2016 926.005.985 77.6%
2017 129.956.633 -612.55%
2018 56.469.032 -130.14%
2019 12.844.633 -339.63%
2020 58.076.380 77.88%
2021 29.277.263 -98.37%
2022 100.618.521 70.9%
2023 -172.373.860 158.37%
2023 -17.149.939 -905.1%
2024 -183.670.520 90.66%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Ningxia Zhongke Biotechnology Co., Ltd. Gross Profit
Year Gross Profit Growth
1995 37.040.523
1996 42.386.396 12.61%
1997 51.236.815 17.27%
1998 49.523.792 -3.46%
1999 66.145.234 25.13%
2000 86.696.461 23.7%
2001 93.707.287 7.48%
2002 84.987.446 -10.26%
2003 59.902.316 -41.88%
2004 93.525.855 35.95%
2005 99.725.152 6.22%
2006 74.458.990 -33.93%
2007 94.159.691 20.92%
2008 162.988.289 42.23%
2009 150.405.051 -8.37%
2010 139.618.844 -7.73%
2011 179.747.695 22.33%
2012 188.310.129 4.55%
2013 207.782.288 9.37%
2014 80.284.427 -158.81%
2015 103.290.679 22.27%
2016 140.379.268 26.42%
2017 91.582.269 -53.28%
2018 46.654.556 -96.3%
2019 2.863.516 -1529.28%
2020 15.421.614 81.43%
2021 23.893.162 35.46%
2022 75.687.703 68.43%
2023 -93.726.008 180.75%
2023 -99.792.298 6.08%
2024 -60.308.356 -65.47%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Ningxia Zhongke Biotechnology Co., Ltd. Net Profit
Year Net Profit Growth
1995 21.882.960
1996 24.692.415 11.38%
1997 28.848.824 14.41%
1998 40.050.318 27.97%
1999 43.664.507 8.28%
2000 50.235.936 13.08%
2001 50.237.173 0%
2002 25.564.937 -96.51%
2003 -27.591.099 192.66%
2004 5.817.323 574.29%
2005 3.734.555 -55.77%
2006 -36.873.841 110.13%
2007 5.238.841 803.85%
2008 5.632.258 6.99%
2009 4.939.190 -14.03%
2010 -53.856.638 109.17%
2011 1.969.995 2833.85%
2012 42.295.278 95.34%
2013 11.074.318 -281.92%
2014 -107.963.614 110.26%
2015 46.088.660 334.25%
2016 -192.020.695 124%
2017 38.230.180 602.28%
2018 9.400.612 -306.68%
2019 -52.062.061 118.06%
2020 20.906.030 349.03%
2021 -29.947.143 169.81%
2022 -170.108.880 82.4%
2023 -333.809.493 49.04%
2023 -465.506.096 28.29%
2024 -1.494.038.052 68.84%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Ningxia Zhongke Biotechnology Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 -1 0%
2024 -2 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Ningxia Zhongke Biotechnology Co., Ltd. Free Cashflow
Year Free Cashflow Growth
1998 -125.125.258
1999 -79.877.325 -56.65%
2000 89.851.376 188.9%
2001 -89.466.337 200.43%
2002 25.107.683 456.33%
2003 692.142 -3527.53%
2004 56.631.688 98.78%
2005 -12.273.020 561.43%
2006 -93.395.941 86.86%
2007 -17.689.190 -427.98%
2008 441.575 4105.93%
2009 82.506.456 99.46%
2010 -211.011.953 139.1%
2011 -254.807.064 17.19%
2012 -172.525.314 -47.69%
2013 -55.536.140 -210.65%
2014 -266.310.104 79.15%
2015 -268.488.903 0.81%
2016 -200.412.203 -33.97%
2017 88.074.383 327.55%
2018 -253.810.294 134.7%
2019 -547.086.475 53.61%
2020 -773.960.002 29.31%
2021 -258.323.595 -199.61%
2022 -6.165.489 -4089.83%
2023 -6.551.840 5.9%
2023 -34.528.173 81.02%
2024 -11.314.483 -205.17%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Ningxia Zhongke Biotechnology Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
1998 -23.133.192
1999 -38.526.847 39.96%
2000 134.167.453 128.72%
2001 40.635.133 -230.18%
2002 53.307.803 23.77%
2003 28.379.716 -87.84%
2004 75.616.113 62.47%
2005 21.458.770 -252.38%
2006 -70.910.649 130.26%
2007 16.206.629 537.54%
2008 47.160.379 65.64%
2009 119.388.375 60.5%
2010 -108.934.831 209.6%
2011 -191.615.638 43.15%
2012 100.105.145 291.41%
2013 5.993.241 -1570.3%
2014 -241.897.813 102.48%
2015 -234.800.344 -3.02%
2016 -191.051.017 -22.9%
2017 115.700.007 265.13%
2018 -180.306.341 164.17%
2019 -47.799.954 -277.21%
2020 -41.059.918 -16.42%
2021 -7.768.637 -428.53%
2022 53.144.180 114.62%
2023 -5.210.939 1119.86%
2023 23.154.120 122.51%
2024 -9.972.914 332.17%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Ningxia Zhongke Biotechnology Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
1998 101.992.066
1999 41.350.478 -146.65%
2000 44.316.077 6.69%
2001 130.101.470 65.94%
2002 28.200.120 -361.35%
2003 27.687.573 -1.85%
2004 18.984.425 -45.84%
2005 33.731.790 43.72%
2006 22.485.293 -50.02%
2007 33.895.819 33.66%
2008 46.718.803 27.45%
2009 36.881.918 -26.67%
2010 102.077.122 63.87%
2011 63.191.425 -61.54%
2012 272.630.459 76.82%
2013 61.529.381 -343.09%
2014 24.412.291 -152.04%
2015 33.688.559 27.54%
2016 9.361.186 -259.87%
2017 27.625.623 66.11%
2018 73.503.954 62.42%
2019 499.286.521 85.28%
2020 732.900.083 31.88%
2021 250.554.959 -192.51%
2022 59.309.669 -322.45%
2023 1.340.901 -4323.12%
2023 57.682.293 97.68%
2024 1.341.569 -4199.61%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Ningxia Zhongke Biotechnology Co., Ltd. Equity
Year Equity Growth
1995 105.937.752
1996 112.026.736 5.44%
1997 113.294.779 1.12%
1998 380.424.701 70.22%
1999 415.268.601 8.39%
2000 439.679.476 5.55%
2001 684.324.343 35.75%
2002 704.272.926 2.83%
2003 690.311.319 -2.02%
2004 694.129.166 0.55%
2005 698.158.020 0.58%
2006 479.552.463 -45.59%
2007 488.251.606 1.78%
2008 497.238.412 1.81%
2009 498.700.139 0.29%
2010 494.441.446 -0.86%
2011 1.045.681.840 52.72%
2012 1.088.450.594 3.93%
2013 1.087.274.591 -0.11%
2014 924.325.893 -17.63%
2015 1.032.214.390 10.45%
2016 902.663.647 -14.35%
2017 1.020.216.356 11.52%
2018 993.202.365 -2.72%
2019 925.105.763 -7.36%
2020 1.272.897.468 27.32%
2021 1.223.208.717 -4.06%
2022 894.081.084 -36.81%
2023 646.229.671 -38.35%
2023 381.990.899 -69.17%
2024 -96.731.655 494.9%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Ningxia Zhongke Biotechnology Co., Ltd. Assets
Year Assets Growth
1995 211.595.055
1996 241.153.104 12.26%
1997 266.025.110 9.35%
1998 510.343.467 47.87%
1999 635.627.619 19.71%
2000 778.592.720 18.36%
2001 1.117.892.139 30.35%
2002 1.238.946.239 9.77%
2003 1.329.178.237 6.79%
2004 1.384.812.746 4.02%
2005 1.416.882.918 2.26%
2006 1.212.250.267 -16.88%
2007 1.323.096.347 8.38%
2008 1.469.982.638 9.99%
2009 1.588.450.112 7.46%
2010 1.807.392.433 12.11%
2011 1.997.858.771 9.53%
2012 2.538.281.756 21.29%
2013 2.561.362.498 0.9%
2014 2.400.794.698 -6.69%
2015 3.922.652.843 38.8%
2016 3.345.941.916 -17.24%
2017 2.299.043.963 -45.54%
2018 2.180.704.990 -5.43%
2019 2.247.718.828 2.98%
2020 3.334.571.091 32.59%
2021 3.465.248.294 3.77%
2022 3.278.697.835 -5.69%
2023 3.136.576.468 -4.53%
2023 2.957.514.548 -6.05%
2024 2.453.334.414 -20.55%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Ningxia Zhongke Biotechnology Co., Ltd. Liabilities
Year Liabilities Growth
1995 105.657.303
1996 129.126.368 18.18%
1997 152.730.331 15.45%
1998 129.918.766 -17.56%
1999 220.359.018 41.04%
2000 338.913.243 34.98%
2001 433.567.794 21.83%
2002 534.673.312 18.91%
2003 638.866.917 16.31%
2004 690.683.579 7.5%
2005 718.724.898 3.9%
2006 732.697.804 1.91%
2007 834.844.740 12.24%
2008 972.744.225 14.18%
2009 1.089.749.973 10.74%
2010 1.312.950.986 17%
2011 952.176.929 -37.89%
2012 1.449.831.161 34.32%
2013 1.474.087.905 1.65%
2014 1.476.468.804 0.16%
2015 2.890.438.452 48.92%
2016 2.443.278.268 -18.3%
2017 1.278.827.607 -91.06%
2018 1.187.502.624 -7.69%
2019 1.322.613.065 10.22%
2020 2.061.673.621 35.85%
2021 2.242.039.576 8.04%
2022 2.384.616.750 5.98%
2023 2.490.346.798 4.25%
2023 2.575.523.648 3.31%
2024 2.532.621.174 -1.69%

Ningxia Zhongke Biotechnology Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.43
Net Income per Share
-1.1
Price to Earning Ratio
-1.81x
Price To Sales Ratio
4.62x
POCF Ratio
35.72
PFCF Ratio
-176.76
Price to Book Ratio
-4.62
EV to Sales
7.11
EV Over EBITDA
-15.62
EV to Operating CashFlow
55.03
EV to FreeCashFlow
-272.34
Earnings Yield
-0.55
FreeCashFlow Yield
-0.01
Market Cap
1,36 Bil.
Enterprise Value
2,10 Bil.
Graham Number
3.27
Graham NetNet
-3.1

Income Statement Metrics

Net Income per Share
-1.1
Income Quality
-0.05
ROE
-7.57
Return On Assets
-0.31
Return On Capital Employed
-1.01
Net Income per EBT
0.94
EBT Per Ebit
1.67
Ebit per Revenue
-1.62
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0.05
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.32
Operating Profit Margin
-1.62
Pretax Profit Margin
-2.72
Net Profit Margin
-2.55

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.02
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.06
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
1.2
Capex to Revenue
0.16
Capex to Depreciation
0.35
Return on Invested Capital
-1.06
Return on Tangible Assets
-0.32
Days Sales Outstanding
46.64
Days Payables Outstanding
573.54
Days of Inventory on Hand
102.73
Receivables Turnover
7.83
Payables Turnover
0.64
Inventory Turnover
3.55
Capex per Share
0.07

Balance Sheet

Cash per Share
0,48
Book Value per Share
-0,12
Tangible Book Value per Share
-0.22
Shareholders Equity per Share
-0.43
Interest Debt per Share
1.32
Debt to Equity
-2.53
Debt to Assets
0.3
Net Debt to EBITDA
-5.48
Current Ratio
0.25
Tangible Asset Value
-0,15 Bil.
Net Current Asset Value
-2,04 Bil.
Invested Capital
385621616
Working Capital
-1,49 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0,05 Bil.
Average Payables
0,62 Bil.
Average Inventory
110894330
Debt to Market Cap
0.55

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Ningxia Zhongke Biotechnology Co., Ltd. Dividends
Year Dividends Growth
2001 0

Ningxia Zhongke Biotechnology Co., Ltd. Profile

About Ningxia Zhongke Biotechnology Co., Ltd.

Ningxia Zhongke Biotechnology Co., Ltd. engages in the manufacturing chemical raw materials and chemical products. It offers coal-based activated carbon and lauric acid products, as well as manufactures bio-based chemical fibers. The company was founded in 1958 and is based in Yinchuan, China.

CEO
Mr. Rui Chen
Employee
731
Address
Hengtai Business Building
Yinchuan,

Ningxia Zhongke Biotechnology Co., Ltd. Executives & BODs

Ningxia Zhongke Biotechnology Co., Ltd. Executives & BODs
# Name Age
1 Mr. Rui Chen
General Manager
70
2 Mr. Baolin Zhang
Board Secretary
70
3 Ms. Chun Xiang Dong
Financial Director
70

Ningxia Zhongke Biotechnology Co., Ltd. Competitors